TY - JOUR
T1 - Pathways linking aging and atheroprotection in Mif- deficient atherosclerotic mice
AU - Krammer, C.
AU - Yang, B.S.
AU - Reichl, S.
AU - Besson-Girard, S.
AU - Ji, H.
AU - Bolini, V.
AU - Schulte, C.
AU - Noels, H.
AU - Schlepckow, K.
AU - Jocher, G.
AU - Werner, G.
AU - Willem, M.
AU - El Bounkari, O.
AU - Kapurniotu, A.
AU - Gokce, O.
AU - Weber, C.
AU - Mohanta, S.
AU - Bernhagen, J.
N1 - Funding Information:
This work was supported by Deutsche Forschungsgemeinschaft (DFG) grant SFB1123-A3 to J.B. and A.K., SFB1123-A1 to C.W., SFB1123-Z1 to S.M., SFB-TRR219-M05 to H.N., and by DFG under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy—ID 390857198) to J.B., O.G., and C.W., and LMUexc strategic partnerships to J.B. C.W. is Van de Laar Professor of Atherosclerosis. We thank Simona Gerra and Priscila Bourilhon for the technical support. We thank Christian Haass for providing access to APP/PS1 and APP/PS1*Trem2−/− mice. The APP/PS1 colony was established from a breeding pair kindly provided by Mathias Jucker (Hertie Institute for Clinical Brain Research, University of Tübingen and DZNE Tübingen). The authors thank Marco Colonna (Washington University, School of Medicine) for the Trem2−/− mice. We also thank Xianyuan Xiang for initial help with the Trem2 antibody staining procedure; Marlies Zarwel for helpful discussions; and Sabrina Pagano, Nicolas Vuilleumier, and Sabine Steffens for advice regarding anti-oxLDL immunoassays. We are grateful to the mouse core facility of the Center for Stroke and Dementia Research (CSD) for their invaluable support with the mouse studies. Open Access funding enabled and organized by Projekt DEAL.
Funding Information:
This work was supported by Deutsche Forschungsgemeinschaft (DFG) grant SFB1123‐A3 to J.B. and A.K., SFB1123‐A1 to C.W., SFB1123‐Z1 to S.M., SFB‐TRR219‐M05 to H.N., and by DFG under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy—ID 390857198) to J.B., O.G., and C.W., and LMUexc strategic partnerships to J.B. C.W. is Van de Laar Professor of Atherosclerosis. We thank Simona Gerra and Priscila Bourilhon for the technical support. We thank Christian Haass for providing access to APP/PS1 and APP/PS1*Trem2 mice. The APP/PS1 colony was established from a breeding pair kindly provided by Mathias Jucker (Hertie Institute for Clinical Brain Research, University of Tübingen and DZNE Tübingen). The authors thank Marco Colonna (Washington University, School of Medicine) for the Trem2 mice. We also thank Xianyuan Xiang for initial help with the Trem2 antibody staining procedure; Marlies Zarwel for helpful discussions; and Sabrina Pagano, Nicolas Vuilleumier, and Sabine Steffens for advice regarding anti‐oxLDL immunoassays. We are grateful to the mouse core facility of the Center for Stroke and Dementia Research (CSD) for their invaluable support with the mouse studies. Open Access funding enabled and organized by Projekt DEAL. −/− −/−
Publisher Copyright:
© 2023 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Atherosclerosis is a chronic inflammatory condition of our arteries and the main underlying pathology of myocardial infarction and stroke. The pathogenesis is age-dependent, but the links between disease progression, age, and atherogenic cytokines and chemokines are incompletely understood. Here, we studied the chemokine-like inflammatory cytokine macrophage migration inhibitory factor (MIF) in atherogenic Apoe(-/-) mice across different stages of aging and cholesterol-rich high-fat diet (HFD). MIF promotes atherosclerosis by mediating leukocyte recruitment, lesional inflammation, and suppressing atheroprotective B cells. However, links between MIF and advanced atherosclerosis across aging have not been systematically explored. We compared effects of global Mif-gene deficiency in 30-, 42-, and 48-week-old Apoe(-/-) mice on HFD for 24, 36, or 42 weeks, respectively, and in 52-week-old mice on a 6-week HFD. Mif-deficient mice exhibited reduced atherosclerotic lesions in the 30/24- and 42/36-week-old groups, but atheroprotection, which in the applied Apoe(-/-) model was limited to lesions in the brachiocephalic artery and abdominal aorta, was not detected in the 48/42- and 52/6-week-old groups. This suggested that atheroprotection afforded by global Mif-gene deletion differs across aging stages and atherogenic diet duration. To characterize this phenotype and study the underlying mechanisms, we determined immune cells in the periphery and vascular lesions, obtained a multiplex cytokine/chemokine profile, and compared the transcriptome between the age-related phenotypes. We found that Mif deficiency promotes lesional macrophage and T-cell counts in younger but not aged mice, with subgroup analysis pointing toward a role for Trem2(+) macrophages. The transcriptomic analysis identified pronounced MIF- and aging-dependent changes in pathways predominantly related to lipid synthesis and metabolism, lipid storage, and brown fat cell differentiation, as well as immunity, and atherosclerosis-relevant enriched genes such as Plin1, Ldlr, Cpne7, or Il34, hinting toward effects on lesional lipids, foamy macrophages, and immune cells. Moreover, Mif-deficient aged mice exhibited a distinct plasma cytokine/chemokine signature consistent with the notion that mediators known to drive inflamm'aging are either not downregulated or even upregulated in Mif-deficient aged mice compared with the corresponding younger ones. Lastly, Mif deficiency favored formation of lymphocyte-rich peri-adventitial leukocyte clusters. While the causative contributions of these mechanistic pillars and their interplay will be subject to future scrutiny, our study suggests that atheroprotection due to global Mif-gene deficiency in atherogenic Apoe(-/-) mice is reduced upon advanced aging and identifies previously unrecognized cellular and molecular targets that could explain this phenotype shift. These observations enhance our understanding of inflamm'aging and MIF pathways in atherosclerosis and may have implications for translational MIF-directed strategies.
AB - Atherosclerosis is a chronic inflammatory condition of our arteries and the main underlying pathology of myocardial infarction and stroke. The pathogenesis is age-dependent, but the links between disease progression, age, and atherogenic cytokines and chemokines are incompletely understood. Here, we studied the chemokine-like inflammatory cytokine macrophage migration inhibitory factor (MIF) in atherogenic Apoe(-/-) mice across different stages of aging and cholesterol-rich high-fat diet (HFD). MIF promotes atherosclerosis by mediating leukocyte recruitment, lesional inflammation, and suppressing atheroprotective B cells. However, links between MIF and advanced atherosclerosis across aging have not been systematically explored. We compared effects of global Mif-gene deficiency in 30-, 42-, and 48-week-old Apoe(-/-) mice on HFD for 24, 36, or 42 weeks, respectively, and in 52-week-old mice on a 6-week HFD. Mif-deficient mice exhibited reduced atherosclerotic lesions in the 30/24- and 42/36-week-old groups, but atheroprotection, which in the applied Apoe(-/-) model was limited to lesions in the brachiocephalic artery and abdominal aorta, was not detected in the 48/42- and 52/6-week-old groups. This suggested that atheroprotection afforded by global Mif-gene deletion differs across aging stages and atherogenic diet duration. To characterize this phenotype and study the underlying mechanisms, we determined immune cells in the periphery and vascular lesions, obtained a multiplex cytokine/chemokine profile, and compared the transcriptome between the age-related phenotypes. We found that Mif deficiency promotes lesional macrophage and T-cell counts in younger but not aged mice, with subgroup analysis pointing toward a role for Trem2(+) macrophages. The transcriptomic analysis identified pronounced MIF- and aging-dependent changes in pathways predominantly related to lipid synthesis and metabolism, lipid storage, and brown fat cell differentiation, as well as immunity, and atherosclerosis-relevant enriched genes such as Plin1, Ldlr, Cpne7, or Il34, hinting toward effects on lesional lipids, foamy macrophages, and immune cells. Moreover, Mif-deficient aged mice exhibited a distinct plasma cytokine/chemokine signature consistent with the notion that mediators known to drive inflamm'aging are either not downregulated or even upregulated in Mif-deficient aged mice compared with the corresponding younger ones. Lastly, Mif deficiency favored formation of lymphocyte-rich peri-adventitial leukocyte clusters. While the causative contributions of these mechanistic pillars and their interplay will be subject to future scrutiny, our study suggests that atheroprotection due to global Mif-gene deficiency in atherogenic Apoe(-/-) mice is reduced upon advanced aging and identifies previously unrecognized cellular and molecular targets that could explain this phenotype shift. These observations enhance our understanding of inflamm'aging and MIF pathways in atherosclerosis and may have implications for translational MIF-directed strategies.
KW - aging
KW - artery tertiary lymphoid organ
KW - atherosclerosis
KW - atypical chemokines
KW - chemokines
KW - MIF
KW - MIGRATION INHIBITORY FACTOR
KW - INFLAMMATION
KW - EXPRESSION
KW - DISEASE
KW - LYMPHOCYTES
KW - INNATE
KW - CELLS
KW - ATHEROGENESIS
KW - CHOLESTEROL
KW - MECHANISMS
U2 - 10.1096/fj.202200056R
DO - 10.1096/fj.202200056R
M3 - Article
C2 - 36794636
SN - 0892-6638
VL - 37
JO - Faseb Journal
JF - Faseb Journal
IS - 3
M1 - e22752
ER -